Lomitapide
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Lomitapide: From Homozygous Familial Hypercholesterolemia to Hyperlipoproteinemia
One-Sentence Summary
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor originally developed and used for homozygous familial hypercholesterolemia (HoFH). Among the 10 TxGNN-predicted indications in this evidence pack, only Hyperlipoproteinemia is backed by real-world evidence — 12 clinical trials and 19 publications — while the nine higher-ranked candidates (all rare platelet disorders) have zero clinical trials or literature and appear to be a systematic prediction artifact rather than genuine signals.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Homozygous Familial Hypercholesterolemia (HoFH) — inferred from clinical evidence context; no formal Taiwan/EU license record is available in this dataset |
| Predicted New Indication | Hyperlipoproteinemia (rank 9 of 10; the only candidate with supporting evidence) |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L1 |
| EU Market Status | Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Note on the top-ranked candidates: TxGNN’s highest-scoring predictions (rank 1–8, 10; scores 0.995–0.999) are all rare platelet/hemostasis disorders — e.g. marcothrombocytopenia with mitral valve insufficiency, Glanzmann thrombasthenia, dense granule disease. None have any supporting clinical trial or literature evidence, and the evidence pack itself flags this as a likely systematic clustering bias in the knowledge graph rather than a genuine mechanistic signal. These are scored “Hold” and are not discussed further in this report.
Why is This Prediction Reasonable?
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor. It blocks the assembly and secretion of hepatic VLDL and intestinal chylomicrons, thereby directly lowering ApoB-containing lipoproteins (LDL-C). This is the drug’s well-established core pharmacology, already exploited clinically in HoFH.
“Hyperlipoproteinemia” as a predicted indication is not a mechanistically distant “new use” — it is a broader disease-classification term that encompasses HoFH and related dyslipidemias. In other words, the TxGNN model is largely re-identifying the drug’s known therapeutic space rather than proposing a genuinely novel repurposing hypothesis. The supporting trials (see below) are overwhelmingly Lomitapide-in-HoFH studies (adult, pediatric, Japanese, and long-term follow-on populations), plus one related program in familial chylomicronemia syndrome (FCS), which is mechanistically adjacent (triglyceride/ApoB metabolism).
Given the drug’s original MOA and the disease overlap, the biological plausibility is high — but this should be framed as evidence consolidation/label-adjacent expansion rather than true repurposing into an unrelated therapeutic area.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04681170 | Phase 3 | Completed | 46 | Single-arm, open-label study of Lomitapide efficacy/long-term safety in pediatric HoFH patients on stable lipid-lowering therapy |
| NCT00730236 | Phase 3 | Completed | 29 | Pivotal registration trial of AEGR-733 (Lomitapide) in HoFH; basis for original approval |
| NCT02173158 | Phase 3 | Completed | 9 | Efficacy/safety of Lomitapide in Japanese HoFH patients on concurrent lipid-lowering therapy |
| NCT00943306 | Phase 3 | Completed | 19 | Long-term follow-on study confirming continued efficacy/safety of Lomitapide in HoFH |
| NCT02135705 | N/A | Recruiting | 300 | LOWER Registry — global, long-term, prospective observational cohort on real-world safety/effectiveness |
| NCT06832371 | N/A | Active, not recruiting | 73 | Observational study evaluating major adverse cardiovascular events (MACE) in HoFH patients on Lomitapide |
| NCT00690443 | Phase 2 | Completed | 44 | Randomized, double-blind trial of AEGR-733 + atorvastatin vs. atorvastatin monotherapy in moderate hypercholesterolemia |
| NCT00559962 | Phase 2 | Completed | 260 | Randomized, placebo-controlled study of low-dose MTP inhibitor on hepatic fat accumulation |
| NCT01556906 | Phase 2 | Completed | 6 | Open-label dose-escalation study establishing safety/tolerability of Lomitapide across 4 dose levels in HoFH |
Three trials (NCT02399852, NCT02765841 — both withdrawn with 0 enrollment; NCT05611528 — an Evinacumab trial, not Lomitapide) were excluded as low-relevance or off-target.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39426393 | 2024 | Phase 3 Study | Lancet Diabetes Endocrinol | APH-19: efficacy/safety results of Lomitapide in pediatric HoFH patients on standard-of-care lipid-lowering therapy |
| 40494715 | 2025 | Review | J Clin Lipidol | Over 10 years of long-term efficacy and safety experience with Lomitapide in HoFH |
| 36152419 | 2022 | Review | Atherosclerosis | Efficacy/safety of Lomitapide extended to familial chylomicronemia syndrome (FCS) |
| 35148370 | 2022 | Review | Eur J Prev Cardiol | Understanding the efficacy and safety of Lomitapide in HoFH |
| 33829367 | 2021 | Review | Advances in Therapy | Real-world case reports of Lomitapide use in HoFH patients in Saudi Arabia |
| 31741187 | 2019 | Review | Curr Atheroscler Rep | Lomitapide and Mipomersen — MTP and apoB100 synthesis inhibition mechanisms |
| 28598687 | 2017 | Review | Expert Opin Pharmacother | Lomitapide for the treatment of hypercholesterolemia |
| 25936301 | 2015 | Review | Atherosclerosis Suppl | Mipomersen and Lomitapide as new HoFH treatment options |
| 24231894 | 2014 | Review | J Cardiovasc Nurs | Lomitapide and Mipomersen — novel lipid-lowering agents for FH management |
| 21846156 | 2011 | Review | Am J Cardiovasc Drugs | Early development review of Lomitapide as an MTP inhibitor for hypercholesterolemia |
EU Market Information
Lomitapide is currently not marketed in this dataset’s regulatory registry (market status: Not marketed, total authorizations: 0). No marketing authorization records are available to summarize.
Safety Considerations
Structured safety fields (key warnings, contraindications, DDI) are marked as data gaps (DG001, severity: Blocking) and could not be populated from TFDA/EMA sources in this pack.
Contextual note from the evidence review: one prediction rationale in this pack independently flags that Lomitapide carries serious hepatotoxicity and teratogenicity warnings, consistent with its known boxed-warning profile as an MTP inhibitor. This has not been formally verified against a parsed SmPC/label in this evidence pack.
Please refer to the SmPC for complete safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 2/3 trials and a substantial literature base support Lomitapide’s efficacy in the HoFH/hyperlipoproteinemia space, but this largely reflects the drug’s already-established therapeutic use rather than a novel repurposing opportunity. Formal safety documentation (TFDA/EMA label) is missing and is flagged as a Blocking gap, preventing a full S1 safety assessment.
To proceed, the following is needed:
- TFDA/EMA product label (warnings, contraindications) to close the Blocking data gap (DG001) before any safety-stage evaluation
- Confirmed mechanism of action data via DrugBank API to formally close DG002 (currently inferred only from trial/literature narrative)
- Clarification of whether “Hyperlipoproteinemia” represents a distinct regulatory opportunity or is already covered under existing HoFH indications in relevant markets
- No further action recommended on the nine platelet-disorder predictions (ranks 1–8, 10) unless independent mechanistic or clinical evidence emerges — current pattern is consistent with a knowledge-graph prediction artifact
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.